Vivos Inc (RDGL)

[kayak_wench]

What matters is Vivos has publications, not whether the CEO is an author of the publication. It is silly to argue otherwise as a CEO leads the company he does not do the research both are full time jobs.

Here is the citation from the first feline study, in a peer reviewed journal, published May 2018 in the Journal of Nuclear Medicine.
"Interstitial Therapy of Feline Sarcoma using an Injectable Y-90-Polymer Composite (Radiogel)"
http://jnm.snmjournals.org/content/59/supplement_1/1257.short

They didn't only publish the cat study they got it accepted into one of the most highly regarded medical journals. Take a look at how highly that is regarded http://jnm.snmjournals.org/content/58/8/1185.full (which notes the journal has "highest number of citations, the highest 5-year average Journal Impact Factor, the highest number of citable articles, and the highest Article Influence Score.

When the dog study is complete it will also be published in a highly respected peer reviewed journal.

You don't get into a journal like that by trying to publish a study that is not complete.

He presented at the conference because he is the face of the study and could do that if he choose to. But he can't put himself on a journal article and wouldn't if he didn't contribute technically. Korenko will likely not be an author on the dog study as he doesn't do the research he leads the company.

So much for your response. Your attempt to down play the technical relevance of Vivos contributions is amusing.